Published in J Carcinog on January 01, 2009
Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol (1996) 15.20
What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst (1990) 13.41
Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell (2005) 9.18
Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol (2002) 7.76
Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun (1971) 2.67
The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res (2007) 2.13
Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci U S A (1995) 2.09
N-nitrosomethylurea as mammary gland carcinogen in rats. J Natl Cancer Inst (1975) 1.99
Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res (1997) 1.83
Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res (1996) 1.81
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells. Clin Cancer Res (2008) 1.56
Epidermal growth factor receptor in tumor angiogenesis. Hematol Oncol Clin North Am (2004) 1.44
Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy. Ann Oncol (2006) 1.17
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biol Reprod (2005) 1.06
VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest (2005) 1.04
Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins. Expert Rev Anticancer Ther (2004) 1.03
Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. Curr Pharm Des (2005) 1.00
Growth and characterization of N-methyl-N-nitrosourea-induced mammary tumors in intact and ovariectomized rats. Carcinogenesis (2001) 1.00
Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res (2005) 0.99
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer (2006) 0.95
Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Biol Reprod (2003) 0.95
Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin Cancer Res (2002) 0.92
Coexpression of the IGF-IR, EGFR and HER-2 is common in colorectal cancer patients. Int J Oncol (2006) 0.92
Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril (2004) 0.92
Regulation of targeted chemotherapy with cytotoxic lutenizing hormone-releasing hormone analogue by epidermal growth factor. Cancer Res (2000) 0.90
Tumor growth enhancing effects of vascular endothelial growth factor are associated with increased nitric oxide synthase activity and inhibition of apoptosis in human breast carcinoma xenografts. Cancer Lett (2002) 0.85
Pharmacology of the luteinising hormone-releasing hormone (LHRH) analogue, Zoladex. Horm Res (1989) 0.84
Does the EGFR and VEGF expression predict the prognosis in colon cancer? Eur Surg Res (2006) 0.82
Prolactin, TNF alpha and nitric oxide expression in nitroso-N-methylurea-induced-mammary tumours. J Carcinog (2007) 0.79
Use of analogues of luteinizing hormone-releasing hormone for the treatment of cancer. J Reprod Fertil (1982) 0.79
Effects of the luteinizing-hormone-releasing hormone (LHRH) antagonist ramorelix (hoe013) and the LHRH agonist buserelin on dimethylbenz[]anthracene-induced mammary carcinoma: studies with slow-release formulations. J Cancer Res Clin Oncol (1993) 0.78
Epidermal growth factor in NMU-induced mammary tumors in rats. Breast Cancer Res Treat (1998) 0.78
Endocrine and antitumor effects of combined treatment with an antiprogestin and antiestrogen or luteinizing hormone-releasing hormone agonist in female rats bearing mammary tumors. Endocrinology (1989) 0.77
Resistance to mammary carcinogenesis in Copenhagen rats: potential roles of vascular endothelial growth factor and mast cells. Cancer Lett (2002) 0.77
Erythrocyte aminolevulinate dehydratase activity as a lead marker in patients with chronic renal failure. Am J Kidney Dis (2002) 0.96
Hepcidin treatment in Hfe-/- mice diminishes plasma iron without affecting erythropoiesis. Eur J Clin Invest (2010) 0.91
Sp1 and Sp3 transcription factors mediate leptin-induced collagen α1(I) gene expression in primary culture of male rat hepatic stellate cells. Endocrinology (2012) 0.80
Single nucleotide change in the cannabinoid receptor-1 (CNR1) gene in colorectal cancer outcome. Oncology (2009) 0.80
Increased mitochondrial respiratory chain enzyme activities correlate with minor extent of liver damage in mice suffering from erythropoietic protoporphyria. Exp Dermatol (2005) 0.79
Sialoadenectomy alters liver cell turn-over and function in mice. J Cell Physiol (2004) 0.77
Bone marrow transplantation into hemochromatotic mice decreases hepatic and duodenal iron overload. Int J Biochem Cell Biol (2007) 0.76
Blockade of endothelial G(i) protein enhances early engraftment in intraportal cell transplant to mouse liver. Cell Transplant (2012) 0.75
Mutation in CNR1 gene and VEGF expression in esophageal cancer. Tumori (2009) 0.75
Vectorization of ultrasound-responsive nanoparticles in placental mesenchymal stem cells for cancer therapy. Nanoscale (2017) 0.75
[Surgical treatment of multiresistant lung tuberculosis]. Biomedica (2004) 0.75